# A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct07544056/  
OnCo record `nct07544056` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing BEBT-209 in triple-negative breast cancer, now recruiting.

## Summary

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer is a phase 2/3 interventional study registered as NCT07544056, led by BeBetter Med with Hunan Cancer Hospital and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multi-centre, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative Breast Cancer. Planned enrolment is 446 participants (estimated). The study started in 2026-06-04 and primary completion is expected in 2030-06. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07544056
- Phase: 2/3
- Setting: A Randomized, Controlled, Open-label, Multi-center, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Sponsor: BeBetter Med
- Enrolled: 446

## Sources

- ClinicalTrials.gov NCT07544056: https://clinicaltrials.gov/study/NCT07544056

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [BEBT-209](https://onco.cc/drugs/bebt-209/)
- companies: [BeBetter Med](https://onco.cc/companies/bebetter-med/)

---
JSON: https://onco.cc/api/v1/entities/nct07544056.json